acyclovir
acyclovir: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
acyclovir evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could acyclovir → RDY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) Reported 2020-06-17 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)
Primary endpoint: Brain Magnetic Resonance Imaging (MRI) Assessment: Adjusted Number of New or Enlarged T2 Lesions Per Month
Frequently asked questions
Which companies have sourced relationships with acyclovir?
acyclovir has dated SEC/FDA relationship records for DR REDDYS LABORATORIES LTD.
How many clinical trials involve acyclovir?
BioSniper tracks 1 clinical trial involving acyclovir.
What is acyclovir's latest FDA decision?
The most recent tracked FDA decision for acyclovir is Approval, dated June 17, 2020.